<DOC>
	<DOCNO>NCT00424671</DOCNO>
	<brief_summary>This study assess influence moderate hepatic impairment pharmacokinetics licarbazepine single oral administration healthy subject subject stable impaired hepatic function .</brief_summary>
	<brief_title>Effect Moderate Hepatic Impairment Pharmacokinetics Metabolism Single Dose Licarbazepine</brief_title>
	<detailed_description />
	<criteria>Control group hepatically impaired group : Male and/or female subject 18 65 year age . Female subject must surgically sterilize postmenopausal ( Postmenopausal woman must regular menstrual bleeding least 2 year prior inclusion . Menopause confirm plasma FSH level &gt; 40 IU/L . Female subject must surgically sterilize least 6 month prior screen . Surgical sterilization procedure must support clinical documentation make available sponsor note Relevant Medical History / Current Medical Conditions section CRF ) Able communicate well investigator , understand comply requirement study . The subject must able provide write informed consent prior study participation , thus exclude subject encephalopathy grade 3 4 . Body mass index ( BMI ) must within range 18 32 . For instruction table see Appendix 5 . Hepatically impaired group : Subjects must liver cirrhosis ( hepatic fibrosis evidence either micro macronodular regeneration ) confirm image technique , ultrasound , MRI CT . Subjects must physical sign consistent clinical diagnosis liver cirrhosis ( e.g. , liver firmness palpation , splenic enlargement , spider angioma , palmar erythema , parotid hypertrophy , testicular atrophy , gynecomastia ) . Subjects must ChildPugh Clinical Assessment Score 7 9 screening baseline . Vital sign ( 3 minute rest supine position ) within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 100180 mm Hg diastolic blood pressure , 60115 mm Hg pulse rate , 60 100 bpm Subjects creatinine clearance great 50 mL/min ( base Cockcroft Gault formula ) Control group : Subjects must good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Subjects match hepatically impaired group gender , age ( ±10 % ) , smoke status , BMI ( ±10 % ) . At Screening , Baseline , vital sign ( systolic diastolic blood pressure pulse rate ) assess subject rest least three ( 3 ) minute , require three ( 3 ) minute stand position . Vital sign within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 90140 mm Hg diastolic blood pressure , 5090 mm Hg pulse rate , 40 90 bpm When blood pressure pulse take 3 minute stand , shall 20 mm Hg drop systolic 10 mm Hg drop diastolic blood pressure increase heart rate ( &gt; 20 bpm ) associate clinical manifestation postural hypotension . All blood pressure measurement timepoints assess subject supine , unless state otherwise protocol design , utilizing arm determination . Control group hepatically impaired group : Participation clinical investigation experimental drug therapy within four week prior dose longer required local regulation . Donation loss 400 mL blood within two month prior dose . Significant acute , new onset illness ( ie , flu , gastroenteritis ) within two week prior dosi4 . A past medical history clinically significant ECG abnormality family history ( grandparent , parent sibling ) prolong QTinterval syndrome . History hyponatremia seizure . History autonomic dysfunction . Subjects consistent , abnormally low total lymphocyte count ( &lt; 10 % total white blood cell count ) A known hypersensitivity drug . History immunocompromise , include positive HIV ( ELISA Western blot ) test result . Evidence active alcohol drug abuse indicate laboratory assay conduct screen baseline evaluation . Smokers report cigarette use 20 cigarette per day . Urine cotinine level measure screening . Hepatically impaired group : Subjects history unstable , severe , clinically significant cardiovascular disease Polymorphonuclears &lt; 1000/µL platelet &lt; 100 ’ 000/µL inclusion . Subjects clinically significant abnormal finding , consistent underlie disease , upon physical examination , ECG laboratory evaluation . Subjects frank symptom encephalopathy ataxia . A recent history acute chronic bronchospastic disease , include asthma chronic obstructive pulmonary disease , treat treated . Any surgical medical condition might significantly alter absorption , distribution , excretion drug . Current drug treatment mood stabilizer , psychotropic drug antiepileptic . Patients must willing able forgo treatment restrict medication throughout study . Approved prescription medication allow course study case case basis patient standard treatment regimen least 3 month continue regular regimen without change throughout study ( unless require protocol treat adverse event ) Treatments table 5.1 allow hepatically impaired group . Control group Use prescription medication within 1 month prior dose . Use overthecounter medication vitamins 14 day prior dose ( Paracetamol , aspirin ibuprofen acceptable , must document CRF ) . History presence liver disease liver injury indicate abnormal liver function profile SGOT , SGPT , GGT , alkaline phosphate , serum bilirubin . Hepatitis B indicate positive HBs Ag positive antiHBc IgM result , Hepatitis C indicate positive antiHCV result . History acute chronic bronchospastic disease , include asthma chronic obstructive pulmonary disease , treat treated . Any surgical medical condition might significantly alter absorption , distribution , excretion drug . The investigator guide evidence following : History inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleeding , chronic diarrhoea ; History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; History pancreatic injury pancreatitis ; indication impair pancreatic function/injury indicate abnormal lipase amylase ; History presence impair renal function indicate abnormal creatinine BUN value abnormal urinary constituent ( e.g. , albuminuria ) ; History urinary obstruction difficulty void polymorphonuclears &lt; 1000/µL platelet &lt; 100 ’ 000/µL inclusion . Known history autoimmune disease SLE Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>